To determine the potential efficacy of KRAS inhibition against murine KRAS/TP53‐driven MPM, C57BL/6 mice received pleural KPM1 cells, followed by a single intrapleural injection of liposomal‐encapsulated KRAS inhibitor deltarasin (15 mg/kg; Zimmermann et al, 2013) or empty liposomes on day nine post‐tumor cells, in order to allow initial tumor implantation in the pleural space (Agalioti et al, 2017). The gene discussed is TP53; the disease is neoplasm.